Robert Dickey, IV, MBA, is the CFO for South Rampart Pharma. Mr. Dickey has over two decades of experience as a CFO and COO in public, private, revenue stage, and development stage companies and has played a leading role in two start-ups. He has expertise in public and private financings, M & M&A, partnering/licensing transactions, project management, and building organizations, and interacting with Boards, venture capitalists, shareholders, and Wall Street. His previous career as an investment banker, mostly at Lehman Brothers, involved deal experience split between M & M&A and capital markets transactions in various industries, including consumer goods, energy, and high technology. To date, Mr. Dickey has raised over $90 million in private company financings, over $200 million for public companies, and over $1 billion as an investment banker. Previously, he helped grow a company from 4 to 60+ employees and filed for an IPO with a valuation of ~$400 million. He has international experience involving equity fundraising on the London Exchange, a joint venture in India; stock repurchase in Taiwan; and research collaborations and M & M&A with Japanese companies. Partnering and Licensing Experience include significant roles in negotiating/monitoring collaborations with Academia Sinica (Taiwan), Amgen, Dow, Ono Pharmaceuticals (Japan), Rutgers, University of Pennsylvania, and Weill Cornell. Financial Management Experience includes preparing SEC and London AIM public filings, creating and upgrading accounting and finance functions in the U.S. and internationally, and preparing Board materials. Mr. Dickey earned an A.B. in Economics (Princeton University) and a Master of Business Administration with a Concentration in Finance (The Wharton School, University of Pennsylvania).